Garry Neil is Chief Executive Officer, President and principal executive officer of Avalo Therapeutics, Inc. (AVTX). The company reported total compensation of $3,807,581 for fiscal year 2025.
| Salary | $590,000 |
|---|---|
| Bonus | — |
| Stock awards | $0 |
| Option awards | $2,732,298 |
| Non-equity incentive plan | $474,950 |
| Pension and non-qualified deferred compensation | — |
| All other compensation | $10,333 |
| Total | $3,807,581 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Avalo Therapeutics, Inc. filed April 10, 2026, accession 0001534120-26-000022.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Garry Neil this page | Chief Executive Officer, President and principal executive officer | $3,807,581 |
| Taylor Boyd | Chief Business Officer | $3,219,751 |
| Mittie Doyle | Chief Medical Officer | $1,780,557 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Avalo Therapeutics, Inc. compensation brief.
Garry Neil's compensation sits inside Avalo Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.